Lisata Therapeutics (LSTA) vs Niki BioSolutions (NIKI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Niki BioSolutions (NIKI) over the past year, losing 52.6% versus a loss of 82.1%. Over five years, LSTA leads with a -93.4% price change compared with -98.3% for NIKI. Niki BioSolutions is the larger company by market cap ($13.5 million vs $13.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LSTA | NIKI |
|---|---|---|
| Share price | $1.20 | $4.32 |
| Market cap | $12.96M | $13.47M |
| 1-day change | +2.56% | -7.10% |
| YTD return | -35.48% | -59.25% |
| 1-year return | -52.57% | -82.07% |
| 5-year return | -93.44% | -98.33% |
| EPS (TTM) | $-1.64 | $-2.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.07 | $24.00 |
| 52-week low | $0.99 | $4.10 |
| Distance from 52-week high | -76.33% | -82.00% |
| Analyst consensus | none | — |
| Average volume | 291.91K | 157.52K |
| Shares outstanding | 10.80M | 2.94M |
| Employees | 21 | 1 |
| Sector | Health Care | Industrials |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSTA has outperformed NIKI by 29.5 percentage points over the past year.
- The two companies sit in different sectors: Lisata Therapeutics in Health Care and Niki BioSolutions in Industrials.
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Niki BioSolutions
NIKI stock →Niki BioSolutions, Inc., through its subsidiaries, operates as a clinical-stage biopharmaceutical company and engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in a Phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in a Phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa.
Industrials · Industrial Machinery/Components · 1 employees
LSTA vs NIKI FAQ
Which is bigger, Lisata Therapeutics or Niki BioSolutions?
Niki BioSolutions (NIKI) is larger, with a market capitalization of $13.47M compared with $12.96M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, LSTA or NIKI?
LSTA returned -52.57% over the past 12 months, compared with -82.07% for NIKI (price return, excluding dividends). Past performance does not predict future results.
Are Lisata Therapeutics and Niki BioSolutions in the same industry?
No. Lisata Therapeutics is in the Health Care sector, while Niki BioSolutions is in Industrials.